Mark Horowitz, MD
Internal Medicine · New York, NYNPI 1154490530
Payments from drug & device makers
Across 335 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$705
- AstraZeneca$534
- Palette Life Sciences, Inc.$448
- Pfizer$446
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1882%
- Food & beverage$7,47694%
- Education$2804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 72 | $2,020 |
| Amgen(2 entities) | 61 | $1,530 |
| Mallinckrodt Hospital Products Inc. | 32 | $705 |
| AstraZeneca(2 entities) | 18 | $534 |
| Palette Life Sciences, Inc. | 9 | $448 |
| Pfizer | 28 | $446 |
| GSK | 25 | $400 |
| Lilly USA, LLC | 17 | $351 |
| Hikma Pharmaceuticals USA | 13 | $268 |
| Novartis | 9 | $187 |
| Gilead | 6 | $150 |
| Mallinckrodt Enterprises LLC | 10 | $140 |
| AbbVie | 5 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $105 |
| Sanofi | 3 | $95 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Merck | 2 | $47 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Eyevance Pharmaceuticals LLC | 2 | $45 |
| LEO Pharma Inc. | 2 | $31 |
| UCB, Inc. | 2 | $25 |
| Bristol Myers Squibb | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$393
- Tremfya$393
- Deflux$165
- KRYSTEXXA$147
How this compares
$7,945 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 40 | $307,462 |
| MounjaroTirzepatide | 17 | $19,043 |
| OzempicSemaglutide | 19 | $17,914 |
| XareltoRivaroxaban | 11 | $11,441 |
| JardianceEmpagliflozin | 13 | $8,231 |
| Levothyroxine Sodium | 226 | $2,856 |
| Atorvastatin Calcium | 202 | $2,740 |
| SynthroidLevothyroxine Sodium | 26 | $2,551 |
| Rosuvastatin Calcium | 108 | $2,325 |
| Celecoxib | 32 | $2,203 |
| Colchicine | 32 | $1,679 |
| Fluvastatin ErFluvastatin Sodium | 13 | $1,584 |
| Hydroxychloroquine Sulfate | 27 | $1,528 |
| Risedronate Sodium | 15 | $1,362 |
| ValacyclovirValacyclovir Hcl | 22 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $351 | $19,04317 claims |
| Johnson & JohnsonXarelto | $2,020 | $11,44111 claims |
| AbbVieSynthroid | $124 | $2,55126 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $47 | $1,67932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.